Does Metformin Help Control DHT Levels That Trigger Androgenic Alopecia?

Understanding DHT and Its Role in Hair Loss

Androgenic alopecia, commonly known as pattern hair loss, is driven primarily by dihydrotestosterone (DHT). DHT is a derivative of testosterone produced by the enzyme 5-alpha reductase. Once formed, DHT binds to androgen receptors in hair follicles, particularly in the scalp's front and crown areas, shortening the hair growth cycle and causing thinner, weaker strands over time. The question many have is whether metformin—a prescription drug for type 2 diabetes—can play a role in reducing DHT levels and, consequently, help control androgenic alopecia.

Why Metformin Entered the Conversation on Hair Loss

Metformin lowers blood glucose by improving insulin sensitivity, reducing hepatic glucose production, and enhancing peripheral glucose uptake. Because insulin resistance and hyperinsulinemia are associated with higher androgen activity, researchers have explored whether metformin might have indirect effects on androgens and hair growth. In polycystic ovary syndrome in particular, elevated insulin is described as driving overproduction of androgens from the ovaries and adrenal glands.

What Research Says About Metformin and DHT Regulation

The research directly linking metformin and DHT is essentially absent. What exists are studies of metformin and circulating androgens in women with polycystic ovary syndrome (PCOS) — a different question, in a different population, with DHT itself rarely measured.

Velazquez and colleagues (Metabolism, 1994) reported that metformin therapy in women with PCOS reduced hyperinsulinemia, insulin resistance and hyperandrogenemia while facilitating normal menses. This early, widely cited work is the origin of the insulin-androgen argument. It measured circulating androgens; it did not measure DHT, scalp tissue, or hair.

Morin-Papunen and colleagues (Journal of Clinical Endocrinology & Metabolism, 2003) ran a randomized study in 17 non-obese women with PCOS, comparing metformin (500 mg twice daily for three months, then 1,000 mg twice daily for three months) with an ethinyl estradiol–cyproterone acetate oral contraceptive. Metformin lowered serum testosterone from 2.7 to 2.0 nmol/L (P = 0.01), lowered fasting insulin, and improved menstrual cyclicity, but produced no change in glucose tolerance or clamp-measured insulin sensitivity. The trial was small, enrolled only women, and again reported no DHT measurement and no hair outcome.

No published human study has measured scalp DHT, 5-alpha reductase activity in the follicle, or hair density in people taking metformin for androgenic alopecia. Any statement about metformin and scalp DHT is therefore inference from systemic androgen data, not a measured result.

The Insulin-Androgen Connection: An Indirect Pathway

The proposed connection between metformin and DHT control lies in metabolic regulation: if insulin sensitivity improves, the hormonal cascade that drives excess androgen production is dampened, and less testosterone is available for conversion to DHT. The size of any such effect on scalp DHT is unknown. The available data support reductions in circulating androgens in women with PCOS, and say nothing about androgen levels inside the hair follicle, where local 5-alpha reductase activity, not serum testosterone, does most of the work.

What the Evidence Suggests—And What It Doesn't

The evidence supports one narrow statement: metformin can reduce total and free testosterone in women with PCOS or insulin resistance. There is no human study directly measuring scalp DHT or hair-density outcomes in people with androgenic alopecia taking metformin, and no trial in men. Clinical evidence for finasteride and dutasteride, both 5-alpha reductase inhibitors, is far stronger and directly targets DHT.

Metformin's mechanism is metabolic, not enzymatic: it acts on glucose and insulin pathways, not on 5-alpha reductase. On the published evidence it cannot be described as a DHT-blocking treatment in the way finasteride or topical anti-androgens are.

The Bottom Line

So, does metformin help control DHT levels that trigger androgenic alopecia? Based on the current evidence, metformin has been shown to reduce circulating androgens in women with PCOS, but there is no direct evidence that it reduces scalp DHT or prevents hair follicle miniaturization. Whether people with metabolic conditions see any secondary hair benefit has not been tested.

Metformin is a prescription medicine with its own risks, monitoring requirements and contraindications — it is not a hair-loss treatment and is not approved for one. Talk to a doctor or pharmacist before starting, stopping or combining metformin, and do not take someone else's prescription. If you are being treated for PCOS, insulin resistance or diabetes, changes to that treatment are a decision for your prescriber.

References

Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994). Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43(5), 647–654. https://pubmed.ncbi.nlm.nih.gov/8177055/

Morin-Papunen, L., Vauhkonen, I., Koivunen, R., Ruokonen, A., Martikainen, H., & Tapanainen, J. S. (2003). Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism, 88(1), 148–156. https://pubmed.ncbi.nlm.nih.gov/12519844/